For Immediate Release
Unraveling the Mechanism of Antisense Oligonucleotides -- Research from the Crooke Lab
Contact: Kathryn Ryan
New Rochelle, NY, February 2, 2017—Stanley T. Crooke, MD, PhD, CEO of Ionis Pharmaceuticals and recipient of the 2016 Lifetime Achievement Award from the Oligonucleotide Therapeutic Society presents a detailed look at the mechanisms that underlie antisense drug activity in the article entitled “Molecular Mechanisms of Antisense Oligonucleotides,” published in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers. The article is available Open Access on the Nucleic Acid Therapeutics website.
Dr. Crooke draws on his extensive experience and long career focused on developing antisense oligonucleotide (ASO) therapeutics and highlights the contributions his group has made over the years to characterizing the three main phases of antisense drug action: prehybridization, hybridization, and post-hybridization. He describes the design of ASO therapeutics, how they can be targeted to and hybridize with a target RNA sequence, and the various mechanisms by which ASO drugs are able to degrade, disable, or modify a target RNA--which depends on how they are designed--to inhibit the expression of a specific gene.
“This retrospective will allow our researchers a greater insight into how passion and commitment can truly translate technical development and acumen into therapeutic realities,” says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI.
About the Journal
Nucleic Acid Therapeutics is an authoritative peer-reviewed journal published bimonthly in print and online that focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. The Journal is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center and Annemieke Aartsma-Rus, PhD, Leiden University Medical Center, and Executive Editor Graham C. Parker, PhD. Nucleic Acid Therapeutics is the official journal of the Oligonucleotide Therapeutics Society. Complete tables of content and a sample issue may be viewed on the Nucleic Acid Therapeutics website.
About the Society
The Oligonucleotide Therapeutics Society is an open, non-profit forum to foster academia- and industry-based research and development of oligonucleotide therapeutics. The society brings together the expertise from different angles of oligonucleotide research to create synergies and to bring the field of oligonucleotides to its full therapeutic potential.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Human Gene Therapy, ASSAY and Drug Development Technologies, Applied In Vitro Toxicology, and DNA and Cell Biology. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.